Circulating tumor cell (CTC) enumeration and changes following treatment have been demonstrated to be superior to PSA response in determining mCRPC outcome in patients receiving AR signaling inhibitors but not taxanes.
Plasma AR status has been identified as a potential biomarker of response in metastatic castration-resistant prostate cancer (mCRPC) patients receiving docetaxel or AR-targeted therapies. However, the relevance of plasma AR in the overall management of CRPC patients receiving different docetaxel doses is unknown.
Despite consensus guidelines, many men with low-grade prostate cancer are not managed with active surveillance. Patient perception of the nomenclature used to describe low-grade prostate cancers may partly explain this discrepancy.
Prostate cancer (PCa) is the most frequent cancer among men in Europe. Differences in PCa incidence around the world can be partly explained by variations in recommendations for prostate-specific antigen (PSA), particularly for early detection.
Androgen-deprivation therapy (ADT) via targeting androgens/androgen receptor (AR) signals may suppress cell proliferation in both prostate cancer (PCa) and bladder cancer (BCa), yet its impact on the cell invasion of these two urological cancers remains unclear.
The bladder cuff management and its surgical approach represent an essential and debated step in radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). The objective of our study was to determine which bladder-cuff management has the best oncological outcomes in terms of bladder recurrence-free survival ( BRFS).
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU medical oncologist and Associate Professor of Medicine at Northwestern University in Chicago. I’m so excited to talk today with a good friend and colleague, Dr. Chris Sweeney, who is a Professor of Medicine at the Harvard Medical School, as well as being a […]
Two main endourological modalities standout today for kidney stones treatment, the retrograde intrarenal surgery (RIRS) and the percutaneous nephrolithotomy (PCNL), by and large, the former for small stones (< 2 cm) and the latter for larger stones (> 2 cm), but technological refinements have broadened both approaches’ indications. Moreover, the miniaturized PCNL (mPCNL) has proved […]
While telehealth is not new, the COVID-19 public health emergency declaration in the United States resulted in changes to regulations and reimbursement, resulting in a massive expansion of telehealth use.1 In the last year, urologists and male infertility specialists had to quickly adapt and incorporate telehealth as an option for patients to undergo new evaluations or […]
Imaging-based biomarker research is gaining momentum in oncology due to its non-invasive nature and the potential for monitoring tumor dynamics during treatment. The currently available biomarkers for immune checkpoint inhibitors (ICIs), such as programmed cell death ligand 1 (PD-L1) expression, tumor mutational burden, and tumor-infiltrating lymphocytes, have inherent limitations in predicting treatment outcomes. Different imaging-based […]
